Table 4 |
|||
|
Multivariate logistic regression of dependent variable cancer versus any TZD therapy (Rosiglitazone or Pioglitazone) and potential confounders stratified by gender |
|||
|
Odds ratio |
P |
95% CI |
|
|
|
|||
|
Women (N = 535) |
|||
|
TZD therapy |
2.07 |
0.01 |
1.18–3.63 |
|
Age |
1.02 |
0.25 |
0.99–1.04 |
|
Biguanide use |
1.63 |
0.09 |
0.93–2.84 |
|
Sulfonylurea use |
0.49 |
0.02 |
0.27–0.89 |
|
Glycosolated hemoglobin A1C, % |
0.94 |
0.59 |
0.76–1.17 |
|
Body mass index, kg/m2 |
0.97 |
0.07 |
0.93–1.00 |
|
Cigarette smoking |
0.43 |
0.06 |
0.18–1.03 |
|
High comorbidity conditions |
2.90 |
0.001 |
1.56–5.41 |
|
Number of prescription medications |
1.09 |
0.03 |
1.01–1.18 |
|
|
|||
|
Men (N = 448) |
|||
|
TZD therapy |
1.20 |
0.63 |
0.58–2.46 |
|
Age |
1.05 |
0.01 |
1.01–1.08 |
|
Biguanide use |
0.99 |
0.97 |
0.51–1.91 |
|
Sulfonylurea use |
1.22 |
0.56 |
0.63–2.35 |
|
Glycosolated hemoglobin A1C, % |
0.83 |
0.22 |
0.62–1.12 |
|
Body mass index, kg/m2 |
0.97 |
0.32 |
0.91–1.03 |
|
Cigarette smoking |
0.78 |
0.62 |
0.30–2.03 |
|
High comorbidity conditions |
4.29 |
<0.001 |
2.11–8.72 |
|
Number of prescription medications |
0.89 |
0.018 |
0.80–0.98 |
|
|
|||
|
TZD, thiazolidinedione. |
|||
|
Ramos-Nino et al. BMC Medicine 2007 5:17 doi:10.1186/1741-7015-5-17 |
|||
